Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Protein Expression Changes in Ovarian Cancer during the Transition from Benign to Malignant.

  • Sofia Waldemarson
  • Morten Krogh
  • Ayodele Alaiya
  • Ufuk Kirik
  • Kjell Schedvins
  • Gert Auer
  • Karin M Hansson
  • Reto Ossola
  • Ruedi Aebersold
  • Hookeun Lee
  • Johan Malmström
  • Peter James
Publishing year: 2012
Language: English
Pages: 2876-2889
Publication/Series: Journal of Proteome Research
Volume: 11
Issue: 5
Document type: Journal article
Publisher: The American Chemical Society

Abstract english

Epithelial ovarian carcinoma has in general a poor prognosis since the vast majority of tumors are genomically unstable and clinically highly aggressive. This results in rapid progression of malignancy potential while still asymptomatic and thus in late diagnosis. It is therefore of critical importance to develop methods to diagnose epithelial ovarian carcinoma at its earliest developmental stage, that is, to differentiate between benign tissue and its early malignant transformed counterparts. Here we present a shotgun quantitative proteomic screen of benign and malignant epithelial ovarian tumors using iTRAQ technology with LC-MALDI-TOF/TOF and LC-ESI-QTOF MS/MS. Pathway analysis of the shotgun data pointed to the PI3K/Akt signaling pathway as a significant discriminatory pathway. Selected candidate proteins from the shotgun screen were further confirmed in 51 individual tissue samples of normal, benign, borderline or malignant origin using LC-MRM analysis. The MRM profile demonstrated significant differences between the four groups separating the normal tissue samples from all tumor groups as well as perfectly separating the benign and malignant tumors with a ROC-area of 1. This work demonstrates the utility of using a shotgun approach to filter out a signature of a few proteins only that discriminates between the different sample groups.


  • Biophysics
  • Immunology in the medical area


  • CREATE Health
  • ISSN: 1535-3893
Peter James
E-mail: peter [dot] james [at] immun [dot] lth [dot] se


Department of Immunotechnology

+46 46 222 14 96

+46 70 247 79 60